Compare GSK plc (GSK) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? GSK plc trades at $46.32 (market cap $91.88B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $25.63 (market cap $2.03B). The key difference: GSK plc is far larger — about 45.3× Direxion Daily 20 Year Treasury Bull 3X Shares's market cap, and GSK plc pays a 3.9% dividend while Direxion Daily 20 Year Treasury Bull 3X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Direxion Daily 20 Year Treasury Bull 3X Shares for 28 Days on average.
| GSK | TMF | |
|---|---|---|
Market Cap | $91.88B | $2.03B |
Volume | 7,730,529 | 12,241,664 |
Sector | Health | Fixed Income |
52-Week High | $61.18 | $44.14 |
52-Week Low | $43.24 | $25.19 |
Typical Hold Time | 93 Days | 28 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
TMF, the Direxion Daily 20+ Year Treasury Bull 3X ETF, trades at $25.64 with a 1.61% daily gain amid elevated volume. Technical indicators show a bearish bias with moving averages signaling sell pressure, though oscillators are neutral. The ETF saw increased trading activity with over 5.2 million shares changing hands, as reported by Defense World on October 3, 2026. A dividend of $0.35 is scheduled for payment on September 29, 2026.
The outlook for TMF remains tied to long-term Treasury bond performance, with current technical weakness suggesting near-term pressure. Investment opportunity exists for investors bullish on declining long-term interest rates, but risks include interest rate volatility and the leveraged nature of the ETF amplifying losses. Market sentiment appears mixed given conflicting technical signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
